Novel Delivery of Mtor Inhibitor to Glioblastoma Cells
School Name
South Carolina Governor's School for Science & Mathematics
Grade Level
12th Grade
Presentation Topic
Cell and Molecular Biology
Presentation Type
Mentored
Abstract
Glioblastoma Multiforme (GBM) is an incurable brain cancer. Limited chemotherapeutic options are available to treat GBM. mTOR inhibitors could reduce GBM growth. Our research shows that GBM cells treated with Rapamycin, an mTOR inhibitor, experienced increased cell cytotoxicity as measured by an MTT cell viability assay. The brain cancer cells were plated in triplicate in 96-well plates and treated with increasing concentrations of free Rapamycin and encapsulated Rapamycin for 24 or 48 hours. MTT reagent, tetrazolium dye, was added to the wells and incubated for 2 hours. UV-VIS spectrophotometry was conducted. Rapamycin killed cells within 24 hours. Without retreatment, the cells recovered within 48 hours. Rapamycin must be in micelles because the blood brain barrier does not let mTOR inhibitors collect in the brain tumors. Micelles were made with PHC, PEG-PE, and Rapamycin, targeted with cRGD peptide and labeled with Dylight fluorophore. Micelle quality was characterized by UV-VIS and DLS. An uptake assay was conducted to quantify micelle uptake in GBM cells. Rapamycin encapsulated micelles (RaM) and targeted Rapamycin encapsulated micelles (TRaM) can be encapsulated in micelles with a diameter of 10-15 nm. Targeting integrins on the surface of GBM cells does not appear to improve uptake of the micelles compared to untargeted micelles. TRaM appears to reduce cell viability (~20%) within 24 hours. However, cells require retreatment daily to maintain cell cytotoxicity. Micelles do have an effect on cell viability and may lead to a more concentrated and localized treated of GBM cells.
Recommended Citation
Kanduri, Vaishnavi, "Novel Delivery of Mtor Inhibitor to Glioblastoma Cells" (2020). South Carolina Junior Academy of Science. 80.
https://scholarexchange.furman.edu/scjas/2020/all/80
Location
Furman Hall 107
Start Date
3-28-2020 10:45 AM
Presentation Format
Oral Only
Group Project
No
Novel Delivery of Mtor Inhibitor to Glioblastoma Cells
Furman Hall 107
Glioblastoma Multiforme (GBM) is an incurable brain cancer. Limited chemotherapeutic options are available to treat GBM. mTOR inhibitors could reduce GBM growth. Our research shows that GBM cells treated with Rapamycin, an mTOR inhibitor, experienced increased cell cytotoxicity as measured by an MTT cell viability assay. The brain cancer cells were plated in triplicate in 96-well plates and treated with increasing concentrations of free Rapamycin and encapsulated Rapamycin for 24 or 48 hours. MTT reagent, tetrazolium dye, was added to the wells and incubated for 2 hours. UV-VIS spectrophotometry was conducted. Rapamycin killed cells within 24 hours. Without retreatment, the cells recovered within 48 hours. Rapamycin must be in micelles because the blood brain barrier does not let mTOR inhibitors collect in the brain tumors. Micelles were made with PHC, PEG-PE, and Rapamycin, targeted with cRGD peptide and labeled with Dylight fluorophore. Micelle quality was characterized by UV-VIS and DLS. An uptake assay was conducted to quantify micelle uptake in GBM cells. Rapamycin encapsulated micelles (RaM) and targeted Rapamycin encapsulated micelles (TRaM) can be encapsulated in micelles with a diameter of 10-15 nm. Targeting integrins on the surface of GBM cells does not appear to improve uptake of the micelles compared to untargeted micelles. TRaM appears to reduce cell viability (~20%) within 24 hours. However, cells require retreatment daily to maintain cell cytotoxicity. Micelles do have an effect on cell viability and may lead to a more concentrated and localized treated of GBM cells.
